Danimer Scientific — Q1 2024 Earnings Presentation
12 slides from Danimer Scientific's earnings presentation, May 7, 2024
Slide 1: First Quarter 2024 Earnings Presentation
First Quarter 2024 Earnings Presentation May 7, 2024
Slide 2: Disclaimer and Forward-Looking Statements
This presentation (“Presentation”) is for informational purposes only. This Presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale w
Slide 3: Fast Facts
FAST FACTS Founded in 2004 (went public in 2020) 480 patents & pending patent applications 15 partnerships with major brands and distributors 238 Teammates 2018 and 2020 recipient of PLASTICS Innovation in Bioplastics Award Locations in Georgia, Kentucky and New York Manufacturer and developer of PH
Slide 4: Sales Cycle
Lead Evaluation Pre-Commercial Launch Material Selection Trials R&D / Product Development Certification Work Market Testing Regulatory Initial Sample New leads are screened by sales first, then a joint committee with R&D & sales if necessary; many do not make it past this stage 1 – 5 Years 6 Months
Slide 5: Sales Cycle (continued): Material Selection
Material Selection ~ 89 customers currently in “Material Selection” zone. Material selection zone is an iterative process, not necessarily a linear process. Sales Cycle (continued) Material Selection Trials R&D / Product Development Certification Work Market Testing Regulatory Initial Sample 5
Slide 6: Warrant Dividend to Deleverage Balance Sheet and Reset Capital Structure
Provides unique opportunity to deleverage our balance sheet and reset our capital structure. 1 for 3 Pro-Rata Dividend – Record Date May 13, 2024 1 warrant for each 3 shares outstanding Expect approximately 46.7 million warrants would be issued to eligible participants $5.00 Exercise Price – Cash or
Slide 7: Q1 2024 Financial Summary
Q1 2024 Financial Summary Q1’24 sales overall decreased compared to Q1’23 driven by higher PHA sales of $3.2M, which did not fully offset lower PLA sales of ($4.3M) where were lower due to the impact of the Ukraine conflict. Increased adjusted gross loss primarily impacted by lower sales as compared
Slide 8: Fiscal 2024 Guidance Summary
Adjusted EBITDA guidance towards the lower end of previously announced range of $(22) million to $(32) million. Capital expenditures guidance range of $8 million to $10 million. Year-end liquidity, which comprises our unrestricted cash and projected availability under the revolver will be in the ran
Slide 9: tess, ~ e
AN y . tess, ~ e Zé danimer \ oe soienutic. ‘y __ ABiotechnology Company
Slide 10: Adjusted EBITDA Reconciliation
Adjusted EBITDA Reconciliation 10
Slide 11: Adjusted Gross Profit Reconciliation
Adjusted Gross Profit Reconciliation 11
Slide 12: Thank You
a danimer ~ scientific THANK YOU